Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition
Open Access
- 16 May 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 68 (1) , 87-95
Abstract
Demographic data show an increasingly aging human immunodeficiency virus (HIV) population worldwide. Recent concerns over dolutegravir-related neuropsychiatric toxicity have emerged, particularly amongst older people living with HIV (PLWH). We describe the pharmacokinetics (PK) of dolutegravir (DTG) 50 mg once daily in PLWH aged 60 and older. Additionally, to address calls for prospective neuropsychiatric toxicodynamic data, we evaluated changes in sleep quality and cognitive functioning in this population after switching to abacavir (ABC)/lamivudine (3TC)/DTG over 6 months. PLWH ≥60 years with HIV–viral load max) was significantly higher in patients ≥60 years old versus controls (geometric mean 4246 ng/mL versus 3402 ng/mL, P = .005). In those who completed day 180 (n = 38), sleep impairment (Pittsburgh Sleep Quality Index) was marginally higher at day 28 (P = .02), but not at days 90 or 180. Insomnia, daytime functioning, and fatigue test scores did not change statistically over time. DTG Cmax was significantly higher in older PLWH. Our data provides clinicians with key information on the safety of prescribing DTG in older PLWH.Keywords
Funding Information
- ViiV Healthcare (SSAT064)
This publication has 34 references indexed in Scilit:
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 StudyThe Journal of Infectious Diseases, 2014
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 InfectionNew England Journal of Medicine, 2013
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyThe Lancet, 2013
- Comparison of polysomnographic data in age-, sex- and Axis I psychiatric diagnosis matched HIV-seropositive and HIV-seronegative Insomnia PatientsClinical Neurophysiology, 2012
- Prevalence and impact of sleep disorders and sleep habits in the United StatesSleep and Breathing, 2009
- Pharmacokinetics and drug metabolism in the elderlyDrug Metabolism Reviews, 2009
- The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test batteryArchives of Clinical Neuropsychology, 2006
- Validation of the Insomnia Severity Index as an outcome measure for insomnia researchSleep Medicine, 2001
- The Fatigue Severity ScaleArchives of Neurology, 1989
- The Pittsburgh sleep quality index: A new instrument for psychiatric practice and researchPsychiatry Research, 1989